Marketing Firsts Due As Amryt’s Filsuvez And Roche’s Lunsumio Win EU Nod

No Decision Yet On Eladocagene Exuparvovec And Olipudase Alfa

Amryt’s epidermolysis bullosa gel and Roche’s CD20xCD3 bispecific antibody for follicular lymphoma are among four drugs that have received the thumbs up from the European Medicines Agency.

New drugs are on track to being approved in the EU • Source: Alamy

The European Medicines Agency has recommended that two first-of-a-kind treatments be approved across the EU – Amryt Pharma’s Filsuvez (birch bark extract), for epidermolysis bullosa, and Roche’s Lunsumio (mosunetuzumab), for follicular lymphoma.

Filsuvez, a topical gel that was rejected in the US in February, is now set to be authorized for use...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet